$AXDX
Accelerate Diagnostics, Inc Stock $axdx

$axdx Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000162828016021126 Filed on November 09, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$39.00K	$24.00K	$92.00K
YoY Change	77.27%	-73.91%	475.0%
Cost Of Revenue		$0.00
YoY Change
Gross Profit	$39.00K	$24.00K
YoY Change
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$10.22M	$9.310M	$4.330M
YoY Change	72.34%	115.01%	64.64%
% of Gross Profit	26205.13%	38791.67%
Research & Development	$5.250M	$7.874M	$6.499M
YoY Change	-12.79%	21.16%	9.23%
% of Gross Profit	13461.54%	32808.33%
Depreciation & Amortization	$590.0K	$598.0K	$465.0K
YoY Change	0.0%	28.6%	72.22%
% of Gross Profit	1512.82%	2491.67%
Operating Expenses	$16.06M	$7.874M	$6.499M
YoY Change	28.07%	21.16%	-26.48%
Operating Profit	-$16.02M	-$17.42M	-$11.21M
YoY Change		55.4%
Interest Expense	$160.0K	$120.0K	$20.00K
YoY Change		500.0%	100.0%
% of Operating Profit
Other Income/Expense, Net		$0.00	-$1.000K
YoY Change		-100.0%
Pretax Income	-$15.87M	-$17.30M	-$11.19M
YoY Change	26.76%	54.59%	27.01%
Income Tax	$270.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.14M	-$17.30M	-$11.19M
YoY Change	22.58%	54.65%	26.91%
Net Earnings / Revenue	-41371.79%	-72079.17%	-12158.7%
Basic Earnings Per Share
Diluted Earnings Per Share	-$313.6K	-$337.6K	-$250.2K
COMMON SHARES
Basic Shares Outstanding	51.44M shares	51.24M shares	44.73M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.80M	$90.20M	$39.00M
YoY Change	-41.24%	131.28%	-45.76%
Cash & Equivalents	$19.24M	$28.73M	$25.19M
Short-Term Investments	$58.50M	$61.40M	$13.80M
Other Short-Term Assets	$183.0K	$102.0K	$1.100M
YoY Change	1425.0%	-90.73%	57.14%
Inventory	$0.00
Prepaid Expenses
Receivables	$0.00	$200.0K	$700.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$78.45M	$91.68M	$40.90M
YoY Change	-41.52%	124.16%	-43.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.258M	$4.802M	$3.700M
YoY Change	-15.11%	29.78%	60.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.404M	$4.951M	$3.900M
YoY Change	-14.87%	26.95%	56.0%
TOTAL ASSETS
Total Short-Term Assets	$78.45M	$91.68M	$40.90M
Total Long-Term Assets	$4.404M	$4.951M	$3.900M
Total Assets	$82.85M	$96.63M	$44.80M
YoY Change	-40.53%	115.7%	-40.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$992.0K	$2.400M	$1.600M
YoY Change	-62.18%	50.0%	45.45%
Accrued Expenses	$3.000M	$2.000M	$2.000M
YoY Change	20.0%	0.0%	185.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$100.0K
YoY Change		-100.0%	0.0%
Total Short-Term Liabilities	$4.036M	$4.449M	$3.600M
YoY Change	-23.94%	23.58%	71.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00	$1.000M	$1.000M
YoY Change	-100.0%	0.0%	25.0%
Total Long-Term Liabilities	$0.00	$1.000M	$1.000M
YoY Change	-100.0%	0.0%	11.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.036M	$4.449M	$3.600M
Total Long-Term Liabilities	$0.00	$1.000M	$1.000M
Total Liabilities	$5.036M	$5.449M	$4.600M
YoY Change	-20.14%	18.46%	58.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$177.3M	-$161.2M
YoY Change	59.84%
Common Stock	$255.3M	$252.3M
YoY Change	4.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$77.82M	$91.18M	$40.20M
YoY Change
Total Liabilities & Shareholders Equity	$82.85M	$96.63M	$44.80M
YoY Change	-40.53%	115.7%	-40.43%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$16.14M	-$17.30M	-$11.19M
YoY Change	22.58%	54.65%	26.91%
Depreciation, Depletion And Amortization	$590.0K	$598.0K	$465.0K
YoY Change	0.0%	28.6%	72.22%
Cash From Operating Activities	-$12.80M	-$12.52M	-$8.880M
YoY Change	29.42%	40.99%	43.69%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	-$220.0K	-$430.0K
YoY Change	-89.72%	-48.84%	-31.75%
Acquisitions
YoY Change
Other Investing Activities	$2.750M	$3.240M	-$900.0K
YoY Change	41.03%	-460.0%	125.0%
Cash From Investing Activities	$2.650M	$3.020M	-$1.330M
YoY Change	201.14%	-327.07%	29.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	780.0K	720.0K	180.0K
YoY Change	-99.25%	300.0%	-220.0%
NET CHANGE
Cash From Operating Activities	-12.80M	-12.52M	-8.880M
Cash From Investing Activities	2.650M	3.020M	-1.330M
Cash From Financing Activities	780.0K	720.0K	180.0K
Net Change In Cash	-9.370M	-8.780M	-10.03M
YoY Change	-109.82%	-12.46%	36.28%
FREE CASH FLOW
Cash From Operating Activities	-$12.80M	-$12.52M	-$8.880M
Capital Expenditures	-$110.0K	-$220.0K	-$430.0K
Free Cash Flow	-$12.69M	-$12.30M	-$8.450M
YoY Change	43.88%	45.56%	52.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	110000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	13000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2400000	USD
	dei	Amendment Flag AmendmentFlag	false
CY2016Q3	axdx	Additional Exercised Class Of Warrant Or Right Exercise Price Of Warrants Or Rights AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2
CY2016Q3	axdx	Additional Exercised Option Indexedto Issuers Equity Indexed Shares AdditionalExercisedOptionIndexedtoIssuersEquityIndexedShares	143344	shares
CY2015Q4	axdx	Deferred Revenue Research Use Only DeferredRevenueResearchUseOnly	114000	USD
CY2016Q3	axdx	Deferred Revenue Research Use Only DeferredRevenueResearchUseOnly	44000	USD
CY2015Q4	axdx	Exercised Warrant Amount Unexercised ExercisedWarrantAmountUnexercised	571160	shares
CY2016Q3	axdx	Exercised Warrant Amount Unexercised ExercisedWarrantAmountUnexercised	427816	shares
	axdx	Proceeds From Recoveryof Related Party Short Swing Profits ProceedsFromRecoveryofRelatedPartyShortSwingProfits	0	USD
	axdx	Proceeds From Recoveryof Related Party Short Swing Profits ProceedsFromRecoveryofRelatedPartyShortSwingProfits	866000	USD
	axdx	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	542000	USD
	axdx	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	864000	USD
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Four RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour	65	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone One RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne	15	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Three RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree	40	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Two RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo	30	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Number Of Milestones RevenueRecognitionMilestoneMethodNumberOfMilestones	4	milestone
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000727207
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51436947	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Accelerate Diagnostics, Inc.
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2543000	USD
CY2016Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2005000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2623000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6778580	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7439375	shares
CY2015Q4	us-gaap	Assets Assets	139324000	USD
CY2016Q3	us-gaap	Assets Assets	96632000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	134151000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	91681000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	132424000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2622000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4367000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	243894000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	252295000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1810000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5995000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2670000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6591000	USD
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3000	USD
CY2016Q3	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	90153000	USD
CY2015Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11851000	USD
CY2016Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	61424000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	11839000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	61422000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	31000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	33000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11851000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	61424000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-28372000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-91854000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	20406000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28731000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	20403000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	11851000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	41018000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	11839000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	41019000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11839000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	61422000	USD
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	13000	USD
CY2016Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53563000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25191000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120585000	USD
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51191184	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51404551	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51191184	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51404551	shares
CY2015Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	51000	USD
CY2016Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	51000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11189000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32341000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17377000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50236000	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	11299000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	32511000	USD
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	17440000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	50684000	USD
CY2015Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2016Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2016Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000.0	USD
CY2016Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2012Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000.0	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	127000	USD
CY2016Q3	us-gaap	Deferred Revenue DeferredRevenue	44000	USD
CY2015Q4	us-gaap	Deferred Revenue And Credits DeferredRevenueAndCredits	127000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-15000	USD
CY2016Q3	us-gaap	Deferred Revenue And Credits DeferredRevenueAndCredits	44000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
CY2016Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
	us-gaap	Depreciation Depreciation	1194000	USD
	us-gaap	Depreciation Depreciation	1745000	USD
CY2015Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	465000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1194000	USD
CY2016Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	598000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1745000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.98
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	12000000	USD
CY2015Q3	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	15.94
CY2016Q3	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	15.40
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	149000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-42000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-115000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	6000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4332000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11953000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9308000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25983000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-329000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	103000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	664000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	82000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1400000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	670000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-14000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-83000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	90000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	642000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-525000	USD
CY2015Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	21000	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	53000	USD
CY2016Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	159000	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	353000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-147000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-251000	USD
	us-gaap	Licenses Revenue LicensesRevenue	49000	USD
CY2016Q3	us-gaap	Licenses Revenue LicensesRevenue	22000	USD
	us-gaap	Licenses Revenue LicensesRevenue	62000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	16000	USD
CY2015Q4	us-gaap	Investments Investments	11839000	USD
CY2016Q3	us-gaap	Investments Investments	61422000	USD
CY2015Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	208000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	490000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	286000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	826000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	6306000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	5449000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	139324000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96632000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5306000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4449000	USD
CY2015Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1000000	USD
CY2016Q3	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1000000	USD
CY2015Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2016Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	6000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	6000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	432000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	983000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3564000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52215000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25240000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40607000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-11186000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32335000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-17299000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-50239000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11207000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32386000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17416000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50477000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1326000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	79000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	998000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	249000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12000	USD
CY2016Q3	us-gaap	Other Assets Current OtherAssetsCurrent	102000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-70000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	11000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	16000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	16000	USD
CY2015Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	21000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	51000	USD
CY2016Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	117000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	238000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	814000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12418000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	73585000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2594000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2301000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1638000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1267000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80000	USD
CY2015Q3	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	141000	USD
CY2016Q3	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	7716000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	8716000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11307000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	14955000	USD
CY2016Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7204000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7204000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	287000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7638000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9169000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4802000	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	77000	USD
CY2016Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	159000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5016000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5995000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6499000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19356000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7531000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22948000	USD
CY2015Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	647000	USD
CY2016Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1200000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110915000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161154000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	76000	USD
	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	76000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	2000	USD
	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	145000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	92000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	125000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	24000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	207000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6591000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.91
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.89
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0179
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0130
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2689	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	125008	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	998600	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6167170	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6971309	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.91
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.64
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.64
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	15.85
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	19.90
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.82
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M13D
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y5M16D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	66764	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	133018000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	91183000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44727000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44685000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51239000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51216000	shares
	axdx	License Agreement LicenseAgreement	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. LICENSE AGREEMENTS AND GRANTS</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Defense Medical Research and Development Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (“DMRDP”) recommended </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;"> of funding for a proposed </font><font style="font-family:Arial;font-size:10pt;">35</font><font style="font-family:Arial;font-size:10pt;">-month project. The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections. The project will apply the Accelerate Pheno™ system to wound infections and other serious infections secondary to trauma. The Company has invoiced a cumulative total of </font><font style="font-family:Arial;font-size:10pt;">$612,000</font><font style="font-family:Arial;font-size:10pt;"> under this grant which is recorded as an offset to research and development expenses. The amounts invoiced for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$10,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$43,000</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$54,000</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$179,000</font><font style="font-family:Arial;font-size:10pt;">, respectively. The period of performance for this grant was complete as of September 30, 2016.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">National Institute of Health Grant</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2015, the National Institute of Health awarded Denver Health and the Company a </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;"> year, </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;"> grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood. The Company completed the first subaward agreement with Denver Health for services provided as part of this grant on January 31, 2016. A second subward was obtained which continued the period of performance through January 31, 2017. The cumulative award amount under these subawards is </font><font style="font-family:Arial;font-size:10pt;">$818,000</font><font style="font-family:Arial;font-size:10pt;">. The amounts invoiced for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$8,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$467,000</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$67,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$467,000</font><font style="font-family:Arial;font-size:10pt;">, respectively. Amounts invoiced under this grant are recorded as an offset to research and development expenses. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona Commerce Authority</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> installments, upon the achievement of the following milestones:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of </font><font style="font-family:Arial;font-size:10pt;">15</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (as defined below).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 2 – Creation of </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestone 1).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 3 – Creation of </font><font style="font-family:Arial;font-size:10pt;">40</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 4 – Creation of </font><font style="font-family:Arial;font-size:10pt;">65</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least </font><font style="font-family:Arial;font-size:10pt;">$4.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least </font><font style="font-family:Arial;font-size:10pt;">$63,000</font><font style="font-family:Arial;font-size:10pt;"> and offers health insurance benefits and pays at least </font><font style="font-family:Arial;font-size:10pt;">65%</font><font style="font-family:Arial;font-size:10pt;"> of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;">, the Company has collected all of the </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestones. The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are “claw-back” provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the “claw-back” provisions expire in January 2018, we will recognize the grant as an offset to expense. Further details are included in </font><font style="font-family:Arial;font-size:10pt;">Note 8, Deferred Revenue and Income</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has applied for and met the program requirements to receive a “Certificate of Qualification” from the Arizona Commerce Authority (“Authority”), which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&D Refundable Tax Credit Program"). The amounts incurred under this program are recorded as an offset to research and development expenses, and for the </font><font style="font-family:Arial;font-size:10pt;">nine months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$1.2 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$647,000</font><font style="font-family:Arial;font-size:10pt;">, respectively, and </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> amounts were incurred for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">. The refund for the 2014 and 2015 tax years is collected. If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reclassification</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation.</font></div></div>
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. DEFERRED REVENUE AND INCOME</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income. A summary of the balances as of </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font><font style="font-family:Arial;font-size:10pt;"> follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Revenue and Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Products not yet delivered</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current deferred revenue and income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arizona Commerce Authority grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term deferred income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have received </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in </font><font style="font-family:Arial;font-size:10pt;">Note 7, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">September 30, 2016</font><font style="font-family:Arial;font-size:10pt;">, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the “claw-back” provisions under the Grant Agreement expire in January 2018.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-021126-index-headers.html	Edgar Link	pending
0001628280-16-021126-index.html	Edgar Link	pending
0001628280-16-021126.txt	Edgar Link	pending
0001628280-16-021126-xbrl.zip	Edgar Link	pending
accelerate-09302016xexh311.htm	Edgar Link	pending
accelerate-09302016xexh312.htm	Edgar Link	pending
accelerate-09302016xexh32.htm	Edgar Link	pending
axdx-093016x10q.htm	Edgar Link	pending
axdx-20160930.xml	Edgar Link	completed
axdx-20160930.xsd	Edgar Link	pending
axdx-20160930_cal.xml	Edgar Link	unprocessable
axdx-20160930_def.xml	Edgar Link	unprocessable
axdx-20160930_lab.xml	Edgar Link	unprocessable
axdx-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AXDX
Accelerate Diagnostics, Inc Stock $axdx

2016 Q4 Form 10-Q Financial Statement

#000162828016021126 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXDX Accelerate Diagnostics, Inc Stock $axdx

2016 Q4 Form 10-Q Financial Statement

#000162828016021126 Filed on November 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXDX
Accelerate Diagnostics, Inc Stock $axdx